

# Comprehensive Reproductive Screen

**POSITIVE**

## REFERRING HEALTHCARE PROFESSIONAL

NAME	HOSPITAL
------	----------

## INDIVIDUAL

NAME	DOB	AGE	GENDER	ORDER ID
------	-----	-----	--------	----------

PRIMARY SAMPLE TYPE	SAMPLE COLLECTION DATE	CUSTOMER SAMPLE ID
---------------------	------------------------	--------------------

## SUMMARY OF RESULTS

### REPRODUCTIVE AND/OR PERSONAL RISKS

Negative for pathogenic and likely pathogenic variants related to personal disease risks and X-linked conditions.

### CARRIERSHIP(S) OF AUTOSOMAL RECESSIVE DISEASE(S)

The individual is heterozygous for *ABCB11* c.3148C>T, p.(Arg1050Cys), which is pathogenic.

The individual is heterozygous for *DYSF* c.3121C>T, p.(Arg1041Cys), which is likely pathogenic.

The individual is heterozygous for *CEP290* c.6277del, p.(Val2093Serfs\*4), which is pathogenic.

The individual is heterozygous for *PMM2* c.422G>A, p.(Arg141His), which is pathogenic.

The individual is heterozygous for a deletion of exon 7 in the *SMN1* gene. This alteration is classified as pathogenic.

Please see further details below: CARRIERSHIP(S) OF AUTOSOMAL RECESSIVE DISEASE(S).

### SEQUENCING PERFORMANCE METRICS

PANEL	GENES	EXONS / REGIONS	BASES	BASES > 20X	MEDIAN COVERAGE	PERCENT > 20X
Comprehensive Reproductive Screen	460	8126	1516574	1514888	180	99.89

### TARGET REGION AND GENE LIST

The Blueprint Genetics Comprehensive Reproductive Screen (version 1, Jun 10, 2023) Plus Analysis includes sequence analysis and copy number variation analysis of the following genes: *AAAS*, *AARS2*, *ABCA3*, *ABCB11*, *ABCC6\**, *ABCC8*, *ABCD1\**, *ACAD9*, *ACADM*, *ACADS*, *ACADSB*, *ACADVL*, *ACOX1*, *ACSF3*, *ADA*, *ADAMTS2\**, *ADAMTSL4*, *ADGRG1*, *ADGRV1*, *AGA*, *AGL*, *AGPS*, *AGXT*, *AHI1*, *AIFM1*, *AIRE*, *ALDH3A2*, *ALDH7A1*, *ALDOB*, *ALG6*, *ALMS1\**, *ALPL*, *AMT*, *ANO10*, *AP1S1*, *AP3B1*, *AR*, *ARG1*, *ARL6*, *ARSA*, *ARSB*, *ARX\**, *ASL*, *ASNS\**, *ASPA*, *ASS1*, *ATM*, *ATP13A2*, *ATP6V1B1*, *ATP7A*, *ATP7B*, *ATRX*, *AVPR2*, *B9D1*, *B9D2*, *BBS1*, *BBS10*, *BBS12*, *BBS2*, *BBS4*, *BBS5*, *BBS7*, *BBS9*, *BCKDHA*, *BCKDHB*, *BCS1L*, *BLM*, *BRAT1*, *BSND*, *BTD*, *C10ORF2*, *CANT1*, *CAPN3*, *CASQ2*, *CBS*, *CC2D2A\**, *CCDC88C*, *CD40*, *CD40LG*, *CDH23*, *CECR1*, *CENPJ*, *CEP290\**, *CERKL*, *CFTR*, *CHAT*, *CHM\**, *CHRNE*, *CIITA*, *CLCN1*, *CLN3*, *CLN5*, *CLN6*, *CLN8*, *CLRN1*, *CNGA3*, *CNGB3*, *COL27A1*, *COL4A3*, *COL4A4*, *COL4A5*, *COL7A1*, *COLQ*, *CPS1*, *CPT1A*, *CPT2*, *CRB1*, *CTNS*, *CTSD*, *CTSF*, *CTSK*, *CYBA*, *CYBB*, *CYP11B1\**, *CYP11B2\**, *CYP17A1*, *CYP19A1*, *CYP1B1*, *CYP21A2\**, *CYP27A1*, *CYP27B1*, *CYP7B1*, *DBT*, *DCLRE1C\**, *DDX11\**, *DGAT1*, *DHCR7*, *DHDDS*, *DKC1*, *DLD*, *DMD*, *DNAH5*, *DNAI1*, *DNAI2*, *DOK7*, *DYNC2H1*, *DYSF*, *EDA*, *EIF2AK4*, *EIF2B2*, *EIF2B5*, *EMD*, *EPG5*, *ERCC2*, *ERCC6\**, *ERCC6L2*, *ERCC8*, *ESCO2*, *ETFA*,

*ETFB, ETFDH, ETHE1, EVC, EVC2, EXOSC3, EYS\**, *F11, F9, FAH, FAM161A, FANCA, FANCC, FANCE, FANCG, FANCI, FANCL, FH, FHL1\**, *FKRP, FKTN, FMO3, FRAS1, G6PC, GAA, GALC, GALE, GALK1, GALNS, GALNT3, GALT, GAMT, GBA\**, *GBE1, GCDH, GCH1, GCSH, GFM1, GFPT1, GJB1, GJB2, GJB6, GLA, GLB1, GLDC, GLE1, GNE, GNPAT, GNPTAB, GNPTG, GNS, GORAB, GP9, GRHPR, GRIP1, HADH, HADHA, HADHB, HAMP, HAX1, HBA1\**, *HBA2\**,<sup>#</sup>, *HBB, HEXA, HEXB, HFE2, HGD, HGSNAT, HLCS, HMGCL, HOGA1, HPRT1, HPS1\**, *HPS3, HPS4, HPS5, HPS6, HSD17B3, HSD17B4, HSD3B2, HYLS1, IDS\**, *IDUA, IKBKAP, IL2RG, IL7R, IQCB1, ISPD, IVD, JAK3, KCNJ1, KCTD7, KIAA0586\**, *KIF14, L1CAM, LAMA2, LAMA3, LAMB3, LAMC2, LARGE, LCA5, LDLR, LHX3, LIFR, LIG4, LIPA, LIPH, LOXHD1, LRP2, LRPPRC, LYST, MAN2B1, MCCC1, MCCC2, MCOLN1, MCPH1\**, *MED17, MEFV, MESP2, MFSD8, MID1\**, *MKKS, MKS1, MLC1, MMAA, MMAB, MMACHC, MMADHC, MPI, MPL, MPV17, MRE11A, MTHFR, MTM1, MTPP, MUT, MVK, MYO15A, MYO7A, NAGLU, NAGS, NBN, NCF2, NDRG1, NDUFAF5, NDUFAF6, NDUFS4, NDUFS6, NEB\**,<sup>#</sup>, *NGLY1, NPC1, NPC2, NPHP1, NPHP3, NPHS1, NPHS2, NROB1, NR2E3, NTRK1, OAT, OCA2, OPA3, ORC4, OTC, OTOF, PAH, PC, PCCA, PCCB\**, *PCDH15, PCNT, PDHA1, PDHB, PEPD, PET100, PEX1, PEX10, PEX12, PEX2, PEX26, PEX6, PEX7, PFKM, PHGDH, PHKB, PHYH, PKHD1, PLP1, PMM2, PNPO, POLG, POMGNT1, POMT1, POMT2, POR, PPT1, PRF1, PROP1, PRPS1\**, *PSAP, PTS, PUS1, PYGL, PYGM, QDPR, RAB23, RAG1, RAG2, RAPSN, RARS2, RDH12, RECQL4, RMRP, RNASEH2A, RNASEH2B, RNASEH2C, RPE65, RPGR, RPGRIP1, RPGRIP1L\**, *RS1, RTEL1, SACS, SAMHD1, SCO2, SEPSECS, SGCA, SGCB, SGCD, SGCG, SGSH, SLC12A1, SLC12A3, SLC12A6, SLC17A5, SLC19A2, SLC19A3, SLC1A4, SLC22A5, SLC25A13, SLC25A15\**, *SLC25A20, SLC26A2, SLC26A3, SLC26A4, SLC35A2, SLC35A3, SLC37A4, SLC39A4, SLC6A8\**, *SLC7A7, SMARCA1, SMN1\**,<sup>#</sup>, *SMPD1, SPG11, SPG7, SPINK5, SPR, SRD5A2, ST3GAL5, STAR, STS, STXPB2, SUMF1, SURF1, SYNE4, TANGO2, TAT, TBCE, TCIRG1, TCTN2, TECPR2, TECRL, TF, TFR2, TG, TGM1, TH, TMEM107, TMEM216, TMEM231, TMEM67, TMPRSS3, TPO, TPP1, TRAF3IP1, TREX1, TRIM37, TSEN2\**, *TSEN34, TSEN54, TSFM\**, *TTC37, TTC8, TTPA, TYMP, TYR\**, *UBR1, UNC13D, USH1C, USH2A, VPS13A, VPS13B, VPS45\**, *VPS53, VRK1, XPA, XPC, ZFYVE26, ZNF469* and *ZNHIT3\**. The following exons are not included in the panel as they are not covered with sufficient high quality sequence reads: *ADAMTS2* (NM\_021599:11), *CC2D2A* (NM\_020785:7), *CHM* (NM\_001145414:5), *KIAA0586* (NM\_001244189:6, 33), *MCPH1* (NM\_001322042:14), *PCCB* (NM\_001178014:4), *RPGRIP1L* (NM\_015272:23), *TSEN2* (NM\_001321278:12), *TSFM* (NM\_001172696:5), *VPS45* (NM\_001279353:13) and *ZNHIT3* (NM\_001281432:5). This panel targets protein coding exons, exon-intron boundaries ( $\pm 20$  bps) and selected non-coding, deep intronic variants (listed in the SUMMARY OF THE TEST section). This panel should be used to detect single nucleotide variants and small insertions deletions (INDELs) and copy number variations defined as single exon or larger deletions and duplications. This panel should not be used for the detection of repeat expansion disorders or diseases caused by mitochondrial DNA (mtDNA) mutations. The test does not detect balanced translocations or complex rearrangements, and it may not detect low-level mosaicism.

\*Some, or all, of the gene is duplicated in the genome. Read more: <https://blueprintgenetics.com/pseudogene/>

#The gene has suboptimal coverage when >90% of the gene's target nucleotides are not covered at >20x with a mapping quality score of MQ>20 reads.

The sensitivity to detect variants may be limited in genes marked with an asterisk (\*) or number sign (#).

## STATEMENT

### TEST INDICATION

This individual is a 40-year-old. Genetic testing with the Comprehensive Reproductive Screen Panel has been requested.

### CLINICAL REPORT

Sequence and Del/Dup (CNV) analysis using the Blueprint Genetics (BpG) Comprehensive Reproductive Screen Panel detected one or more heterozygous likely pathogenic or pathogenic variants. Please see Carriership(s) of autosomal recessive disease(s) for further details.

STEP	DATE
Order date	
Sample received	
Sample in analysis	
Reported	

(This statement has been prepared by our geneticists and physicians, who have together evaluated the sequencing results.)

*Signature*

Name

Title

## CARRIERSHIP(S) OF AUTOSOMAL RECESSIVE DISEASE(S)

This table includes variants that indicate a heterozygous carrier status of a pathogenic or likely pathogenic variant related to autosomal recessive disorder.

Heterozygous variants related to autosomal recessive disorders are not sufficient to cause disease without a second disease-causing variant on the other parental allele in the same gene. For reproductive risk estimation, genetic testing of a partner is recommended. In addition, genetic counseling is recommended.

### SEQUENCE ALTERATIONS

<b>GENE</b> <b>ABCB11</b>	<b>TRANSCRIPT</b> NM_003742.4	<b>NOMENCLATURE</b> c.3148C>T, p.(Arg1050Cys)	<b>GENOTYPE</b> HET	<b>CONSEQUENCE</b> missense_variant	<b>INHERITANCE</b> AD,AR	<b>CLASSIFICATION</b> <b>Pathogenic</b>
	<b>ID</b> <a href="#">rs72549398</a>	<b>ASSEMBLY</b> GRCh37/hg19	<b>POS</b> 2:169788952	<b>REF/ALT</b> G/A		
	<b>gnomAD AC/AN</b> 3/241292	<b>POLYPHEN</b> probably damaging	<b>SIFT</b> deleterious	<b>MUTTASTER</b> disease causing	<b>PHENOTYPE</b> Cholestasis, Cholestasis, benign recurrent intrahepatic, 2	
<b>GENE</b> <b>DYSF</b>	<b>TRANSCRIPT</b> NM_001130978.2	<b>NOMENCLATURE</b> c.3121C>T, p.(Arg1041Cys)	<b>GENOTYPE</b> HET	<b>CONSEQUENCE</b> missense_variant	<b>INHERITANCE</b> AR	<b>CLASSIFICATION</b> <b>Likely pathogenic</b>
	<b>ID</b> <a href="#">rs144598063</a>	<b>ASSEMBLY</b> GRCh37/hg19	<b>POS</b> 2:71797818	<b>REF/ALT</b> C/T		
	<b>gnomAD AC/AN</b> 51/281918	<b>POLYPHEN</b> probably damaging	<b>SIFT</b> deleterious	<b>MUTTASTER</b> disease causing	<b>PHENOTYPE</b> Miyoshi muscular dystrophy, Muscular dystrophy, limb-girdle, Myopathy, distal, with anterior tibial onset	
<b>GENE</b> <b>CEP290</b>	<b>TRANSCRIPT</b> NM_025114.4	<b>NOMENCLATURE</b> c.6277del, p.(Val2093Serfs*4)	<b>GENOTYPE</b> HET	<b>CONSEQUENCE</b> frameshift_variant	<b>INHERITANCE</b> AR	<b>CLASSIFICATION</b> <b>Pathogenic</b>
	<b>ID</b>	<b>ASSEMBLY</b> GRCh37/hg19	<b>POS</b> 12:88456548	<b>REF/ALT</b> AC/A		
	<b>gnomAD AC/AN</b> 11/224022	<b>POLYPHEN</b> N/A	<b>SIFT</b> N/A	<b>MUTTASTER</b> N/A	<b>PHENOTYPE</b> Bardet-Biedl syndrome, Joubert syndrome, Leber congenital amaurosis, Meckel syndrome, Senior-Loken syndrome	
<b>GENE</b> <b>PMM2</b>	<b>TRANSCRIPT</b> NM_000303.3	<b>NOMENCLATURE</b> c.422G>A, p.(Arg141His)	<b>GENOTYPE</b> HET	<b>CONSEQUENCE</b> missense_variant	<b>INHERITANCE</b> AR	<b>CLASSIFICATION</b> <b>Pathogenic</b>
	<b>ID</b> <a href="#">rs28936415</a>	<b>ASSEMBLY</b> GRCh37/hg19	<b>POS</b> 16:8905010	<b>REF/ALT</b> G/A		
	<b>gnomAD AC/AN</b> 891/224376	<b>POLYPHEN</b> benign	<b>SIFT</b> deleterious	<b>MUTTASTER</b> disease causing	<b>PHENOTYPE</b> Congenital disorder of glycosylation	

### COPY NUMBER ABERRATIONS

<b>GENE</b> <b>SMN1</b>	<b>EVENT</b> COPY NUMBER LOSS	<b>COPY NUMBER</b> 1	<b>GENOTYPE</b> HET	<b>IMPACT</b> SMN1	<b>LINKS</b> <a href="#">UCSC</a>	<b>CLASSIFICATION</b> <b>Pathogenic</b>
	<b>OMIM</b>	<b>PHENOTYPE</b> Spinal muscular atrophy			<b>COMMENT</b> -	

## DETAILS ABOUT THESE FINDINGS

### **ABCB11 c.3148C>T, p.(Arg1050Cys)**

This variant has been reported as heterozygous in a male patient with progressive familial intrahepatic cholestasis (PFIC) diagnosed at birth who also had two heterozygous variants (phase unknown) in *MDR3* gene. The variant was also reported in a female patient with benign recurrent intrahepatic cholestasis (BRIC) together with *ABCB11* p.(Glu135Lys) variant (phase unknown; PMID: [28733223](#)). In addition, it has been reported as homozygous in two siblings and as compound heterozygous together with *ABCB11* IVS19+1G>A variant in two siblings with BRIC (PMID: [5300568](#)). The variant was also reported as compound heterozygous with *ABCB11* c.3904G>T, p.(Glu1302\*) variant in a baby girl with severe cholestasis (PMID: [31015375](#)). Functional *in vitro* analysis of the variant has shown that *ABCB11* p.(Arg1050Cys) variant result an intermediate level (~25% of WT) of expression at the plasma membrane and an immature protein formation (PMID: [17855769](#), [19101985](#)). The variant has been detected by other laboratories in the context of clinical testing and submitted to ClinVar (variation ID [374098](#)).

### **DYSF c.3121C>T, p.(Arg1041Cys)**

*DYSF* c.3121C>T, p.(Arg1041Cys) has been identified in the homozygous state in two patients. One of them was diagnosed with Miyoshi myopathy (PMID: [15469449](#)) and the other one had a diagnosis of autosomal recessive limb-girdle muscular dystrophy-2 (LGMDR2) (PMID: [33610434](#)). Western blot analysis of that patient's muscle biopsy sample showed absent dysferlin protein. The variant has been submitted to ClinVar by other clinical testing laboratories (variation ID [286743](#)).

### **CEP290 c.6277del, p.(Val2093Serfs\*4)**

This variant generates a premature stop codon in exon 46 (of 54 total exons) and is predicted to lead to loss of normal protein function, either through protein truncation or nonsense-mediated mRNA decay. This variant has been reported together with another disease-causing variant in *CEP290* in patients affected with Joubert syndrome or Joubert-syndrome-related disorder (PMID: [17564967](#), [21866095](#), [26092869](#)) The variant has also been detected by other laboratories in the context of clinical testing and submitted to ClinVar (Variation ID: [217621](#)).

### **PMM2 c.422G>A, p.(Arg141His)**


*PMM2* c.422G>A, p.(Arg141His) is a well established pathogenic variant, and has been reported in compound heterozygous state in multiple individuals with *PMM2*-related congenital disorder of glycosylation (*PMM2*-CDG, or CDG1A) (PMID: [9140401](#), [11517108](#), [21541725](#), [24424124](#), [21228398](#), [23988505](#), [11589167](#), [19357119](#), [25192236](#), [30991241](#), [31981409](#), HGMD, ClinVar ID [7706](#)). The variant is well documented as the most frequent pathogenic variant in the *PMM2* gene, present in up to 75% of *PMM2*-CDG patients of Caucasian origin. *PMM2* p.(Arg141His) was first described by Matthijs et al. (1997) in a group of 33 unrelated individuals with confirmed phosphomannomutase deficiency (PMID: [9140401](#)). A subsequent review of 249 patients with *PMM2* variants from six different studies and 23 different countries concluded that the p.(Arg141His) variant accounts for 37 percent of all disease-associated *PMM2* alleles (PMID: [11058895](#)). Interestingly, while the carrier frequency of this variant can be as high as 1 in 60 in some populations, no patient homozygous for this variant has been reported, indicating that it may not be compatible with life in the homozygous state (PMID: [11530212](#), [10854097](#)). Functional studies of the Arg141His mutant enzyme in bacteria demonstrated reduced enzyme stability and catalytic activity below detection limits (PMID: [21541725](#)).






### **Deletion of exon 7 in the SMN1 gene**






This deletion includes at least exon 7 of the *SMN1* gene, and it is considered compatible to a deletion of whole *SMN1* gene. There is limited sensitivity to detect the exact break points of the deletion due to the complexity of the *SMN1* gene region. Homozygous loss of *SMN1*, caused by deletion causes spinal muscular atrophy (SMA; OMIM #[253300](#)); absence of exon 7 of *SMN1* has been identified in about 95% of patients with SMA (PMID: [9950358](#)).

# COVERAGE PLOT - NUCLEAR GENES


Readability of the coverage plot may be hindered by faxing. A high quality coverage plot can be found with the full report on [nucleus.blueprintgenetics.com](http://nucleus.blueprintgenetics.com).











## SUMMARY OF THE TEST

**Laboratory process:** When required, the total genomic DNA was extracted from the biological sample using bead-based method. Quantity of DNA was assessed using fluorometric method. After assessment of DNA quantity, qualified genomic DNA sample was randomly fragmented using non-contact, isothermal sonochemistry processing. Sequencing library was prepared by ligating sequencing adapters to both ends of DNA fragments. Sequencing libraries were size-selected with bead-based method to ensure optimal template size and amplified by polymerase chain reaction (PCR). Regions of interest (exons and intronic targets) were targeted using hybridization-based target capture method. The quality of the completed sequencing library was controlled by ensuring the correct template size and quantity and to eliminate the presence of leftover primers and adapter-adapter dimers. Ready sequencing libraries that passed the quality control were sequenced using the illumina's sequencing-by-synthesis method using paired-end sequencing (150 by 150 bases). Primary data analysis converting images into base calls and associated quality scores was carried out by the sequencing instrument using illumina's proprietary software, generating CBC files as the final output.

**Bioinformatics and quality control:** Base called raw sequencing data was transformed into FAST format using Illumina's software (bcl2fastq). Sequence reads of each sample were mapped to the human reference genome (GRCh37/hq19). Burrows Wheeler Aligner (BWA-MEM) software was used for read alignment. Duplicate read marking, local realignment around indels, base quality score recalibration and variant calling were performed using GATK algorithms (Sentieon) for DNA. Variant data for was annotated using a collection of tools (VcfAnno and VP) with a variety of public variant databases including but not limited to gnomAD, ClinVar and HGMD. The median sequencing depth and coverage across the target regions for the tested sample were calculated based on MQ0 aligned reads. The sequencing run included in-process reference samples) for quality control, which passed our thresholds for sensitivity and specificity. The patient's sample was subjected to thorough quality control measures including assessments for contamination and sample mix-up. Copy number variations (CNVs), defined as single exon or larger deletions or duplications (Del/Dups), were detected from the sequence analysis data using a proprietary bioinformatics pipeline. The difference between observed and expected sequencing depth at the targeted genomic regions was calculated and regions were divided into segments with variable DNA copy number. The expected sequencing depth was obtained by using other samples processed in the same sequence analysis as a guiding reference. The sequence data was adjusted to account for the effects of varying guanine and cytosine content.

**Interpretation:** The clinical interpretation team assessed the pathogenicity of the identified variants by reviewing the relevant scientific literature and manually inspecting the sequencing data if needed. All available evidence of the identified variants was compared to classification criteria. Reporting was carried out using HGNC-approved gene nomenclature and mutation nomenclature following the HGVS guidelines. Benign variants, Likely benign variants, and Variants of uncertain significance (VUS) were not reported. Information about estimated residual risks after negative test result using Blueprint Genetics Reproductive Screen Panels is available on our website: <https://blueprintgenetics.com/residual-risk-table/>

**Variant classification:** Our variant classification follows the Blueprint Genetics Variant Classification Schemes modified from the ACMG guideline 2015. Minor modifications were made to increase reproducibility of the variant classification and improve the clinical validity of the report. The classification and interpretation of the variants) identified reflect the current state of Blueprint Genetics' understanding at the time of this report. Variant classification and interpretation are subject to professional judgment, and may change for a variety of reasons, including but not limited to, updates in classification guidelines and availability of additional scientific and clinical information. This test result should be used in conjunction with the health care provider's clinical evaluation. For questions regarding variant classification updates, please contact us at [support@blueprintgenetics.com](mailto:support@blueprintgenetics.com)

**Databases:** The pathogenicity potential of the identified variants were assessed by considering the predicted consequence of the variant, the degree of evolutionary conservation as well as a number of reference population databases and mutation databases such as, but not limited to, the gnomAD, ClinVar, HGMD Professional and Alamut Visual. In addition, the clinical relevance of any identified CNVs was evaluated by reviewing the relevant literature and databases such as Database of Genomic Variants and DECIPHER. For interpretation of mtDNA variants specific databases including e.g. Mitomap, HmtVar and 1000G were used.

**Confirmation of variants:** Reporting focuses on high-quality variants that meet our stringent NGS quality metrics for a true

positive call but they were not confirmed with alternative methods. Ordering health care professional should consider further confirmation of the reported variants using a diagnostic test.

**Analytic validation:** The detection performance of this panel is expected to be in the same range as our high-quality, clinical grade NGS sequencing assay used to generate the panel data (nuclear DNA: sensitivity for SNVs 99.89%, indels 1-50 bps 99.2%, one-exon deletion 100% and five exons CNV 98.7%, and specificity >99.9% for most variant types). It does not detect very low level mosaicism as a variant with minor allele fraction of 14.6% can be detected in 90% of the cases. Detection performance for mtDNA variants (analytic and clinical validation): sensitivity for SNVs and INDELS 100.0% (10-100% heteroplasmy level), 94.7% (5-10% heteroplasmy level), 87.3% (<5% heteroplasmy level) and for gross deletions 100.0%. Specificity is >99.9% for all.

**Test restrictions:** A normal result does not rule out a pathogenic or likely pathogenic variant in the tested genes since some DNA abnormalities may be undetectable by the applied technology. Test results should always be interpreted in the context of clinical findings, family history, and other relevant data.

**Technical limitations:** This test does not detect the following: complex inversions, gene conversions, balanced translocations, repeat expansion disorders unless specifically mentioned, non-coding variants deeper than #20 base pairs from exon-intron boundary unless otherwise indicated (please see the list of non-coding variants covered by the test). Additionally, this test may not reliably detect the following: low level mosaicism, stretches of mononucleotide repeats, indels larger than 50bp, single exon deletions or duplications, and variants within pseudogene regions/duplicated segments. The sensitivity of this test may be reduced if DNA is extracted by a laboratory other than Blueprint Genetics. Laboratory error is also possible. Please see the Analytic validation above.

**Regulation and accreditations:** This test was developed and its performance characteristics determined by Blueprint Genetics (see Analytic validation). It has not been cleared or approved by the US Food and Drug Administration. This analysis has been performed in a CLIA-certified laboratory (#99D2092375), accredited by the College of American Pathologists (CAP #9257331) and by FINAS Finnish Accreditation Service, (laboratory no. T292), accreditation requirement SFS-EN ISO 15189:2013. All the tests are under the scope of the ISO 15189 accreditation.

## PERFORMING SITE:

BLUEPRINT GENETICS OY, KEILARANTA 16 A-B, 02150 ESPOO, FINLAND Laboratory Director: JUHA KOSKENVUO, MD, PHD, CLIA: 99D2092375

- DNA extraction and QC
- Next-generation sequencing
- Bioinformatic analysis
- Confirmation of sequence alterations
- Confirmation of copy number variants
- Interpretation

## NON-CODING VARIANTS COVERED BY THE PANEL:

NM\_005957.4(*MTHFR*):c.1753-18G>A  
 NM\_005957.4(*MTHFR*):c.-13-28\_-13-27delCT  
 NM\_000478.4(*ALPL*):c.-195C>T  
 NM\_000478.4(*ALPL*):c.793-30\_793-11delGGCATGTGCTGACACAGCCC  
 NM\_024887.3(*DHDDS*):c.441-24A>G  
 NM\_000310.3(*PPT1*):c.\*526\_\*529delATCA  
 NM\_000310.3(*PPT1*):c.125-15T>G  
 NM\_013339.3(*ALG6*):c.347-13C>G  
 NM\_000329.2(*RPE65*):c.246-11A>G  
 NM\_000016.4(*ACADM*):c.388-19T>A  
 NM\_000016.4(*ACADM*):c.600-18G>A  
 NM\_000028.2(*AGL*):c.4260-12A>G

NM\_001918.3(DBT):c.1018-550A>G  
NM\_213653.3(HFE2):c.-89-4dupT  
NM\_000396.3(CTSK):c.244-29A>G  
NM\_000157.3(GBA):c.1225-14\_1225-11delTGTCinsAGT  
NM\_000157.3(GBA):c.589-12C>G  
NM\_000157.3(GBA):c.-150A>G  
NM\_002529.3(NTRK1):c.575-19G>A  
NM\_002529.3(NTRK1):c.851-33T>A  
NM\_002529.3(NTRK1):c.2206-12C>A  
NM\_002529.3(NTRK1):c.2206-11G>A  
NM\_014625.2(NPHS2):c.-164C>T  
NM\_000228.2(LAMB3):c.1133-22G>A  
NM\_000228.2(LAMB3):c.-38+1G>A  
NM\_206933.2(USH2A):c.14583-20C>G  
NM\_206933.2(USH2A):c.9959-4159A>G  
NM\_206933.2(USH2A):c.8845+628C>T  
NM\_206933.2(USH2A):c.7595-2144A>G  
NM\_206933.2(USH2A):c.5573-834A>G  
NM\_206933.2(USH2A):c.486-14G>A  
NM\_206933.2(USH2A):c.-259G>T  
NM\_000124.3(ERCC6):c.2599-26A>G  
NM\_001142763.1(PCDH15):c.-29+1G>C  
NM\_001042465.1(PSAP):c.778-26C>A  
NM\_199292.2(TH):c.1198-24T>A  
NM\_199292.2(TH):c.738-34G>C  
NM\_199292.2(TH):c.-69T>A  
NM\_199292.2(TH):c.-70G>A  
NM\_199292.2(TH):c.-71C>T  
NM\_000518.4(HBB):c.\*132C>A/T  
NM\_000518.4(HBB):c.\*132C>A  
NM\_000518.4(HBB):c.\*132C>T  
NM\_000518.4(HBB):c.\*129T>C  
NM\_000518.4(HBB):c.\*115\_\*116delAA  
NM\_000518.4(HBB):c.\*110\_\*114delTAAAA  
NM\_000518.4(HBB):c.\*113A>G  
NM\_000518.4(HBB):c.\*112A>G/T  
NM\_000518.4(HBB):c.\*112A>T  
NM\_000518.4(HBB):c.\*112A>G  
NM\_000518.4(HBB):c.\*110\_\*111delTA  
NM\_000518.4(HBB):c.\*111A>G  
NM\_000518.4(HBB):c.\*110T>A/C  
NM\_000518.4(HBB):c.\*110T>G  
NM\_000518.4(HBB):c.\*108A>C/G  
NM\_000518.4(HBB):c.\*108A>C  
NM\_000518.4(HBB):c.\*108A>G  
NM\_000518.4(HBB):c.\*93\_\*105delATCTGGATTCTGC  
NM\_000518.4(HBB):c.\*96T>C  
NM\_000518.4(HBB):c.\*74A>G  
NM\_000518.4(HBB):c.\*47C>G  
NM\_000518.4(HBB):c.\*32A>C  
NM\_000518.4(HBB):c.316-14T>G  
NM\_000518.4(HBB):c.316-90A>G  
NM\_000518.4(HBB):c.316-106C>G  
NM\_000518.4(HBB):c.316-146T>G  
NM\_000518.4(HBB):c.316-197C>T

NM\_000518.4(HBB):c.316-260T>C  
NM\_000518.4(HBB):c.315+203\_315+205delTCTinsCC  
NM\_000518.4(HBB):c.93-15T>G  
NM\_000518.4(HBB):c.93-21G>A  
NM\_000518.4(HBB):c.93-22delT  
NM\_000518.4(HBB):c.-12C>T  
NM\_000518.4(HBB):c.-18C>G  
NM\_000518.4(HBB):c.-21T>A  
NM\_000518.4(HBB):c.-29G>A/T  
NM\_000518.4(HBB):c.-31delC  
NM\_000518.4(HBB):c.-31C>T  
NM\_000518.4(HBB):c.-41delT  
NM\_000518.4(HBB):c.-43C>T  
NM\_000518.4(HBB):c.-50A>C  
NM\_000518.4(HBB):c.-50A>G/T  
NM\_000518.4(HBB):c.-75G>T  
NM\_000518.4(HBB):c.-75G>C  
chr11:g.5248326-5248326  
NM\_000518.4(HBB):c.-76A>C  
NM\_000518.4(HBB):c.-77A>G/T  
chr11:g.5248328-5248328  
chr11:g.5248328-5248328  
chr11:g.5248329-5248329  
chr11:g.5248329-5248329  
NM\_000518.4(HBB):c.-78A>C/G  
NM\_000518.4(HBB):c.-79A>G  
chr11:g.5248330-5248330  
chr11:g.5248331-5248331  
chr11:g.5248331-5248331  
NM\_000518.4(HBB):c.-80T>A/C  
NM\_000518.4(HBB):c.-81A>C/G  
chr11:g.5248332-5248332  
chr11:g.5248332-5248332  
chr11:g.5248333-5248333  
chr11:g.5248333-5248333  
NM\_000518.4(HBB):c.-82C>A/T  
NM\_000518.4(HBB):c.-91A>C  
NM\_000518.4(HBB):c.-92C>G  
NM\_000518.4(HBB):c.-100G>A  
NM\_000518.4(HBB):c.-121C>T  
chr11:g.5248373-5248373  
NM\_000518.4(HBB):c.-123A>T  
NM\_000518.4(HBB):c.-126C>A  
NM\_000518.4(HBB):c.-127G>C  
chr11:g.5248384-5248384  
chr11:g.5248387-5248387  
chr11:g.5248387-5248387  
chr11:g.5248387-5248387  
NM\_000518.4(HBB):c.-136C>A/G/T  
NM\_000518.4(HBB):c.-137C>A/G/T  
chr11:g.5248388-5248388  
chr11:g.5248388-5248388  
chr11:g.5248388-5248388  
chr11:g.5248389-5248389  
chr11:g.5248389-5248389

NM\_000518.4(*HBB*):c.-138C>A/T  
chr11:g.5248391-5248391  
NM\_000518.4(*HBB*):c.-142C>T  
NM\_000518.4(*HBB*):c.-143C>G  
NM\_000518.4(*HBB*):c.-151C>T  
chr11:g.5248402-5248402  
NM\_000518.4(*HBB*):c.-152C>A  
NM\_000518.4(*HBB*):c.-240G>A  
NM\_000518.4(*HBB*):c.-273T>C  
NM\_000543.4(*SMPD1*):c.1341-21\_1341-18delAATG  
NM\_000391.3(*TPP1*):c.887-18A>G  
NM\_000352.3(*ABCC8*):c.4412-13G>A  
NM\_000352.3(*ABCC8*):c.3399+13G>A  
NM\_000352.3(*ABCC8*):c.2041-12C>A  
NM\_000352.3(*ABCC8*):c.2041-21G>A  
NM\_000352.3(*ABCC8*):c.2041-25G>A  
NM\_000352.3(*ABCC8*):c.1672-20A>G  
NM\_000352.3(*ABCC8*):c.1333-1013A>G  
NM\_000352.3(*ABCC8*):c.1177-53\_1177-51delGTG  
NM\_000352.3(*ABCC8*):c.-190C>G  
NM\_000536.3(*RAG2*):c.-28G>C  
NM\_005055.4(*RAPSN*):c.193-15C>A  
NM\_005055.4(*RAPSN*):c.-199C>G  
NM\_005055.4(*RAPSN*):c.-210A>G  
NM\_005609.2(*PYGM*):c.661-601G>A  
NM\_005609.2(*PYGM*):c.425-26A>G  
NM\_024649.4(*BBS1*):c.951+58C>T  
NM\_000920.3(*PC*):c.1369-29A>G  
NM\_006019.3(*TCIRG1*):c.-5+1G>C/T  
NM\_006019.3(*TCIRG1*):c.-5+1G>C  
NM\_006019.3(*TCIRG1*):c.-5+1G>T  
NM\_006019.3(*TCIRG1*):c.1887+132T>C  
NM\_006019.3(*TCIRG1*):c.1887+142T>A  
NM\_006019.3(*TCIRG1*):c.1887+146G>A  
NM\_006019.3(*TCIRG1*):c.1887+149C>T  
NM\_000260.3(*MYO7A*):c.-48A>G  
NM\_000260.3(*MYO7A*):c.3109-21G>A  
NM\_000260.3(*MYO7A*):c.5327-14T>G  
NM\_000260.3(*MYO7A*):c.5327-11A>G  
NM\_000260.3(*MYO7A*):c.5857-27\_5857-26insTTGAG  
NM\_000372.4(*TYR*):c.1037-18T>G  
NM\_001080463.1(*DYNC2H1*):c.2819-14A>G  
NM\_001080463.1(*DYNC2H1*):c.6478-16G>A  
NM\_000051.3(*ATM*):c.-174A>G  
NM\_000051.3(*ATM*):c.-31+595G>A  
NM\_000051.3(*ATM*):c.-30-1G>T  
NM\_000051.3(*ATM*):c.2639-384A>G  
NM\_000051.3(*ATM*):c.2839-579\_2839-576delAAGT  
NM\_000051.3(*ATM*):c.3403-12T>A  
NM\_000051.3(*ATM*):c.3994-159A>G  
NM\_000051.3(*ATM*):c.4612-12A>G  
NM\_000051.3(*ATM*):c.5763-1050A>G  
NM\_000051.3(*ATM*):c.8418+681A>G  
NM\_000317.2(*PTS*):c.84-323A>T  
NM\_000317.2(*PTS*):c.84-291A>G

NM\_000317.2(PTS):c.164-716A>T  
NM\_000317.2(PTS):c.187-38dupG  
NM\_001166686.1(PFKM):c.1626-64A>G  
NM\_015665.5(AAAS):c.-405C>T  
NM\_025114.3(CEP290):c.6012-12T>A  
NM\_025114.3(CEP290):c.2991+1655A>G  
NM\_025114.3(CEP290):c.1910-11T>G  
NM\_025114.3(CEP290):c.103-18\_103-13delGCTTTT  
NM\_024312.4(GNPTAB):c.1613-25delA  
NM\_000277.1(PAH):c.\*144A>G  
NM\_000277.1(PAH):c.1199+20G>C  
NM\_000277.1(PAH):c.1199+17G>A  
NM\_000277.1(PAH):c.1066-11G>A  
NM\_000277.1(PAH):c.1066-12delT  
NM\_000277.1(PAH):c.1066-13T>G  
NM\_000277.1(PAH):c.1066-14C>G  
NM\_000277.1(PAH):c.1065+39G>T  
NM\_000277.1(PAH):c.509+15\_509+18delCTTG  
NM\_000277.1(PAH):c.169-13T>G  
NM\_000431.2(MVK):c.769-7dupT  
NM\_004004.5(GJB2):c.-22-2A>C  
NM\_004004.5(GJB2):c.-23+2T>A  
NM\_004004.5(GJB2):c.-23+1G>A  
NM\_004004.5(GJB2):c.-23G>T  
NM\_004004.5(GJB2):c.-259C>T  
NM\_004004.5(GJB2):c.-260C>T  
NM\_000231.2(SGCG):c.-127\_-121delACAGTTG  
NM\_000231.2(SGCG):c.-1+1G>T  
NM\_024570.3(RNASEH2B):c.65-13G>A  
NM\_024570.3(RNASEH2B):c.511-13G>A  
NM\_000053.3(ATP7B):c.3061-12T>A  
NM\_000053.3(ATP7B):c.-78A>C  
NM\_000053.3(ATP7B):c.-123C>A  
NM\_000053.3(ATP7B):c.-128\_-124delAGCCG  
NM\_000053.3(ATP7B):c.-133A>C  
NM\_000053.3(ATP7B):c.-210A>T  
chr13:g.52585894-52585894  
chr13:g.52585897-52585897  
NM\_000053.3(ATP7B):c.-442G>A  
NM\_000282.3(PCCA):c.1285-1416A>G  
NM\_020366.3(RPGRIP1):c.1468-263G>C  
NM\_020366.3(RPGRIP1):c.1611+27G>A  
NM\_020366.3(RPGRIP1):c.2367+23delG  
NM\_020366.3(RPGRIP1):c.2367+23delG  
NM\_020366.3(RPGRIP1):c.2711-13G>T  
NM\_000359.2(TGM1):c.509-329C>T  
NM\_000161.2(GCH1):c.-22C>T  
NM\_013382.5(POMT2):c.1333-14G>A  
NM\_000153.3(GALC):c.\*12G>A  
NM\_000153.3(GALC):c.-66G>C  
NM\_000153.3(GALC):c.-67T>G  
NM\_001201402.1(GALC):c.-74T>A  
NM\_001201402.1(GALC):c.-128C>T  
NM\_000275.2(OCA2):c.1117-11T>A  
NM\_000275.2(OCA2):c.1117-17T>C

NM\_000275.2(OCA2):c.1045-15T>G  
 NM\_000275.2(OCA2):c.574-19A>G  
 NM\_000070.2(CAPN3):c.380-13T>A  
 NM\_000070.2(CAPN3):c.1746-20C>T  
 NM\_173089.1(CAPN3):c.-188G>C  
 NM\_000070.2(CAPN3):c.2184+21G>A  
 NM\_000070.2(CAPN3):c.2185-16A>G  
 NM\_174916.2(UBR1):c.1911+14C>G  
 NM\_174916.2(UBR1):c.1094-12A>G  
 NM\_174916.2(UBR1):c.1094-13A>G  
 NM\_174916.2(UBR1):c.529-13G>A  
 NM\_000338.2(SLC12A1):c.976-14C>G  
 NM\_017882.2(CLN6):c.297+113G>C  
 NM\_000520.4(HEXA):c.1146+18A>G  
 NM\_033028.4(BBS4):c.77-216delA  
 NM\_001113378.1(FANCI):c.1583+142C>T  
 NM\_000517.4(HBA2):c.\*47G>C  
 NM\_000517.4(HBA2):c.\*74\_\*89delCCTTCCTGGTCTTTGA  
 NM\_000517.4(HBA2):c.\*93\_\*94delAA  
 NM\_000517.4(HBA2):c.\*92A>G  
 NM\_000517.4(HBA2):c.\*94A>G  
 NM\_000517.4(HBA2):c.\*94A>C  
 NM\_000517.4(HBA2):c.\*104G>T  
 NM\_000558.3(HBA1):c.\*63\_\*65delCCT  
 NM\_032520.4(GNPTG):c.610-16\_609+28del  
 NM\_001089.2(ABCA3):c.3863-98C>T  
 NM\_001089.2(ABCA3):c.1112-20G>A  
 NM\_001089.2(ABCA3):c.-26-2A>G  
 NM\_000243.2(MEFV):c.-12C>G  
 NM\_000243.2(MEFV):c.-382C>G  
 chr16:g.8891573-8891573  
 NM\_000303.2(PMM2):c.179-25A>G  
 NM\_000303.2(PMM2):c.640-15479C>T  
 NM\_000303.2(PMM2):c.640-23A>G  
 NM\_001171.5(ABCC6):c.4403+11C>G  
 NM\_001171.5(ABCC6):c.3506+15G>A  
 NM\_001171.5(ABCC6):c.1780-29T>A  
 NM\_001171.5(ABCC6):c.1432-22C>A  
 NM\_000086.2(CLN3):c.1056+34C>A  
 NM\_000086.2(CLN3):c.461-13G>C  
 NM\_000339.2(SLC12A3):c.602-16G>A  
 NM\_000339.2(SLC12A3):c.1567+297T>G  
 NM\_000339.2(SLC12A3):c.1670-191C>T  
 NM\_000339.2(SLC12A3):c.2548+253C>T  
 NM\_001145774.1(ADGRG1):c.-435\_-421delCAACGGTTGCCAGGG  
 NM\_001077416.2(TMEM231):c.824-11T>C  
 NM\_000101.3(CYBA):c.288-15C>G  
 NM\_000512.4(GALNS):c.899-167A>G  
 NM\_000512.4(GALNS):c.245-11C>G  
 NM\_000135.3(FANCA):c.4261-19\_4261-12delACCTGCTC  
 NM\_000135.2(FANCA):c.3239+82T>G  
 NM\_000135.2(FANCA):c.2982-192A>G  
 NM\_000135.2(FANCA):c.2778+83C>G  
 NM\_000135.2(FANCA):c.2504+134A>G  
 NM\_000135.2(FANCA):c.2223-138A>G



NM\_000135.2(FANCA):c.1567-20A>G  
 NM\_000135.2(FANCA):c.893+920C>A  
 NM\_004937.2(CTNS):c.-643\_-642insT  
 NM\_001031681.2(CTNS):c.-19-1G>A  
 NM\_001031681.2(CTNS):c.141-24T>C  
 NM\_001031681.2(CTNS):c.971-12G>A  
 NM\_000080.3(CHRNE):c.501-16G>A  
 NM\_000080.3(CHRNE):c.-94G>A  
 NM\_000080.3(CHRNE):c.-95G>A  
 NM\_000080.3(CHRNE):c.-96C>T  
 NM\_000018.3(ACADVL):c.-144\_-132delCCAGCATGCCCCinsT  
 NM\_001270447.1(ACADVL):c.822-27C>T  
 NM\_001270447.1(ACADVL):c.822-11T>G  
 NM\_001270447.1(ACADVL):c.1146+15C>T  
 NM\_001270447.1(ACADVL):c.1252-15A>G  
 NM\_001270447.1(ACADVL):c.1747+23C>T  
 NM\_001031806.1(ALDH3A2):c.681-14T>A/G  
 NM\_001031806.1(ALDH3A2):c.681-14T>A  
 NM\_001031806.1(ALDH3A2):c.681-14T>G  
 NM\_000151.3(G6PC):c.446+39G>A  
 NM\_000151.3(G6PC):c.446+42G>A  
 NM\_153006.2(NAGS):c.-3063C>A  
 NM\_000023.2(SGCA):c.585-31\_585-23delTCTGCTGAC  
 NM\_000023.2(SGCA):c.585-31\_585-24delTCTGCTGA  
 NM\_000023.2(SGCA):c.748-12\_748-11delCTinsAA  
 NM\_015294.3(TRIM37):c.1949-12A>G  
 NM\_000154.1(GALK1):c.-22T>C  
 NM\_199242.2(UNC13D):c.2831-13G>A  
 NM\_199242.2(UNC13D):c.2448-13G>A  
 NM\_199242.2(UNC13D):c.118-307G>A  
 NM\_199242.2(UNC13D):c.118-308C>T  
 NM\_138793.3(CANT1):c.-342+1G>A  
 NM\_000152.3(GAA):c.-32-13T>G  
 NM\_000152.3(GAA):c.-32-13T>A  
 NM\_000152.3(GAA):c.-32-3C>A/G  
 NM\_000152.3(GAA):c.-32-2A>G  
 NM\_000152.3(GAA):c.-32-1G>C  
 NM\_000152.3(GAA):c.-17C>T  
 NM\_000152.3(GAA):c.1076-22T>G  
 NM\_000152.3(GAA):c.2190-345A>G  
 NM\_000152.3(GAA):c.2647-20T>G  
 NM\_000199.3(SGSH):c.249+27\_249+28delGG  
 NM\_000271.4(NPC1):c.1554-1009G>A  
 NM\_000271.4(NPC1):c.882-28A>G/T  
 NM\_000271.4(NPC1):c.882-28A>G  
 NM\_000271.4(NPC1):c.882-28A>T  
 NM\_198129.1(LAMA3):c.4584+22\_4584+24delTCT  
 NM\_138924.2(GAMT):c.391+15G>T  
 NM\_006949.3(STXBP2):c.326-23\_326-16delGCCCCACT  
 chr19:g.11199939-11199939  
 NM\_000527.4(LDLR):c.-267A>G  
 NM\_000527.4(LDLR):c.-228G>C  
 chr19:g.11200000-11200000  
 NM\_000527.4(LDLR):c.-206C>T  
 chr19:g.11200031-11200031

chr19:g.11200032-11200032  
chr19:g.11200032-11200032  
NM\_000527.4(LDLR):c.-191C>A  
NM\_000527.4(LDLR):c.-188C>T  
NM\_000527.4(LDLR):c.-185\_-183delCTT  
NM\_000527.4(LDLR):c.-172G>A  
NM\_000527.4(LDLR):c.-168A>G  
NM\_000527.4(LDLR):c.-163T>C  
NM\_000527.4(LDLR):c.-161A>C  
NM\_000527.4(LDLR):c.-156C>T  
NM\_000527.4(LDLR):c.-155\_-154delACinsTTCTGCAAACCTCCT  
NM\_000527.4(LDLR):c.-155\_-150delACCCCA  
NM\_000527.4(LDLR):c.-155\_-154delACinsTTCTGCAAACCTCCT  
NM\_000527.4(LDLR):c.-155\_-150delACCCCAinsTT  
NM\_000527.4(LDLR):c.-154C>T  
NM\_000527.4(LDLR):c.-153C>T  
NM\_000527.4(LDLR):c.-152C>T  
NM\_000527.4(LDLR):c.-151C>G  
NM\_000527.4(LDLR):c.-150A>G  
NM\_000527.4(LDLR):c.-149C>A  
NM\_000527.4(LDLR):c.-146C>A  
NM\_000527.4(LDLR):c.-142C>G/T  
NM\_000527.4(LDLR):c.-139\_-130delCTCCCCCTGC  
NM\_000527.4(LDLR):c.-140C>A/G/T  
NM\_000527.4(LDLR):c.-138delT  
NM\_000527.4(LDLR):c.-139C>A/G  
NM\_000527.4(LDLR):c.-138T>C  
NM\_000527.4(LDLR):c.-137C>T  
NM\_000527.4(LDLR):c.-136C>G/T  
NM\_000527.4(LDLR):c.-136C>G  
NM\_000527.4(LDLR):c.-136C>T  
NM\_000527.4(LDLR):c.-135C>G  
NM\_000527.4(LDLR):c.-134C>T  
NM\_000527.4(LDLR):c.-124dupA  
NM\_000527.4(LDLR):c.-120C>T  
NM\_000527.4(LDLR):c.-101T>C  
NM\_000527.4(LDLR):c.-99A>G  
NM\_000527.4(LDLR):c.-98C>T  
NM\_000527.4(LDLR):c.-22delC  
NM\_000527.4(LDLR):c.-23A>C  
NM\_000527.4(LDLR):c.-14C>A  
NM\_000527.4(LDLR):c.940+14delC  
NM\_000527.4(LDLR):c.941-13T>A  
NM\_000527.4(LDLR):c.1359-31\_1359-23delGCGCTGATGinsCGGCT  
NM\_000527.4(LDLR):c.1359-25A>G  
NM\_000527.4(LDLR):c.1845+11C>G  
NM\_000527.4(LDLR):c.1845+15C>A  
NM\_000527.4(LDLR):c.2140+86C>G  
NM\_000527.4(LDLR):c.2140+103G>T  
NM\_000527.4(LDLR):c.\*43G>A  
NM\_000159.3(GCDH):c.1244-11A>G  
NM\_000215.3(JAK3):c.2680+89G>A  
NM\_000215.3(JAK3):c.1915-11G>A  
NM\_021175.2(HAMP):c.-153C>T  
NM\_021175.2(HAMP):c.-28G>T

NM\_021175.2(HAMP):c.-25G>A  
 NM\_004646.3(NPHS1):c.1931-17C>A  
 NM\_004646.3(NPHS1):c.1930+11C>A  
 NM\_004646.3(NPHS1):c.-475\_-468delGAGAGAGA  
 NM\_000709.3(BCKDHA):c.\*223T>A  
 chr19:g.44031407-44031407  
 NM\_024301.4(FKRP):c.-272G>A  
 NM\_000183.2(HADHB):c.442+614A>G  
 NM\_000183.2(HADHB):c.442+663A>G  
 NM\_000104.3(CYP1B1):c.-322A>C  
 NM\_000104.3(CYP1B1):c.-337G>T  
 NM\_001114636.1(FANCL):c.375-2033C>G  
 NM\_003494.3(DYSF):c.3443-33A>G  
 NM\_003494.3(DYSF):c.4410+13T>G  
 NM\_003494.3(DYSF):c.4886+1249G>T  
 NM\_003494.3(DYSF):c.5668-824C>T  
 NM\_003494.3(DYSF):c.\*107T>A  
 NM\_003124.4(SPR):c.-13G>A  
 NM\_001298.2(CNGA3):c.-37-1G>C  
 NM\_001271208.1(NEB):c.24220-151C>A  
 NM\_001271208.1(NEB):c.19429-381\_19429-379delTTTinsA  
 NM\_003742.2(ABCB11):c.77-19T>A  
 NM\_152384.2(BBS5):c.619-27T>G  
 NM\_001875.4(CPS1):c.4102-239A>G  
 NM\_004328.4(BCS1L):c.-147A>G  
 NM\_004328.4(BCS1L):c.-50+155T>A  
 NM\_000092.4(COL4A4):c.4334-23A>G  
 NM\_000091.4(COL4A3):c.2224-11C>T  
 NM\_000091.4(COL4A3):c.4028-27A>G  
 NM\_000091.4(COL4A3):c.4462+457C>G  
 NM\_000091.4(COL4A3):c.4463-18dupA  
 NM\_025243.3(SLC19A3):c.980-14A>G  
 NM\_024120.4(NDUFAF5):c.223-907A>C  
 NM\_000022.2(ADA):c.1079-15T>A  
 NM\_000022.2(ADA):c.976-34G>A  
 NM\_001178008.1(CBS):c.-86\_-85+8delAGGTAGAAGA  
 NM\_017424.2(CECR1):c.1082-1113delA  
 NM\_015166.3(MLC1):c.895-226T>G  
 NM\_015166.3(MLC1):c.-42C>T  
 NM\_000487.5(ARSA):c.1108-12C>G  
 NM\_000487.5(ARSA):c.1108-20A>G  
 NM\_004628.4(XPC):c.\*156G>A  
 NM\_004628.4(XPC):c.413-24A>G  
 NM\_000060.2(BTD):c.310-15delT  
 NM\_000060.2(BTD):c.\*159G>A  
 NM\_000094.3(COL7A1):c.8620+26G>A  
 NM\_000094.3(COL7A1):c.8305-12T>A  
 NM\_000094.3(COL7A1):c.7929+11\_7929+26delGATGGGGGCTGGGGGG  
 NM\_000094.3(COL7A1):c.7759-18\_7759-14delCATCTinsTTCA  
 NM\_000094.3(COL7A1):c.5821-19A>G  
 NM\_000094.3(COL7A1):c.5236-23A>G  
 NM\_000094.3(COL7A1):c.2587+40G>A  
 NM\_000094.3(COL7A1):c.977-15G>A  
 NM\_000094.3(COL7A1):c.-187C>T  
 NM\_000094.3(COL7A1):c.-188C>T

NM\_000481.3(AMT):c.-55C>T  
NM\_000158.3(GBE1):c.2053-3358\_2053-3350delGTGTGGTGGinsTGTTTTTTACATGACAGGT  
NM\_000187.3(HGD):c.650-17G>A  
NM\_000187.3(HGD):c.650-56G>A  
NM\_001178014.1(PCCB):c.714+462A>G  
NM\_032383.3(HPS3):c.2888-1612G>A  
NM\_001195794.1(CLRN1):c.254-649T>G  
NM\_003907.2(EIF2B5):c.685-13C>G  
NM\_153717.2(EVC):c.940-150T>G  
NM\_000320.2(QDPR):c.436+2552A>G  
NM\_000253.2(MTTP):c.619-5\_619-2delTTTA  
NM\_000253.2(MTTP):c.1237-28A>G  
NM\_001184705.2(HADH):c.636+471G>T  
NM\_001184705.2(HADH):c.709+39C>G  
NM\_004453.2(ETFDH):c.-75A>G  
NM\_004453.2(ETFDH):c.176-636C>G  
NM\_000128.3(F11):c.-456G>A  
NM\_000128.3(F11):c.595+11A>G  
NM\_000128.3(F11):c.1304+12G>A  
NM\_002185.3(IL7R):c.379+288G>A  
NM\_000082.3(ERCC8):c.173+1119G>C  
NM\_000082.3(ERCC8):c.173+1046A>G  
NM\_022132.4(MCCC2):c.384-20A>G  
NM\_022132.4(MCCC2):c.1073-12C>G  
NM\_000521.3(HEXB):c.1243-17A>G  
NM\_000521.3(HEXB):c.1509-26G>A  
NM\_000521.3(HEXB):c.1613+15\_1613+18dupAAGT  
NM\_000521.3(HEXB):c.1614-16\_1615dupTTCATGTTATCTACAGAC  
NM\_000521.3(HEXB):c.1614-14C>A  
NM\_001199291.1(HSD17B4):c.1285-11C>G  
NM\_003060.3(SLC22A5):c.394-16T>A  
NM\_003060.3(SLC22A5):c.825-52G>A  
NM\_006846.3(SPINK5):c.283-12T>A  
NM\_006846.3(SPINK5):c.1431-12G>A  
NM\_006846.3(SPINK5):c.1820+53G>A  
NM\_000112.3(SLC26A2):c.-26+2T>C  
NM\_006261.4(PROPI):c.343-11C>G  
NM\_000500.7(CYP21A2):c.293-13C>G  
NM\_000287.3(PEX6):c.2301-15C>G  
NM\_000287.3(PEX6):c.2300+28G>A  
NM\_000255.3(MUT):c.-39-1G>A  
NM\_138694.3(PKHD1):c.8798-459C>A  
NM\_138694.3(PKHD1):c.7350+653A>G  
NM\_001142800.1(EYS):c.-448+5G>A  
NM\_020320.3(RARS2):c.613-3927C>T  
NM\_000426.3(LAMA2):c.3175-22G>A  
NM\_000426.3(LAMA2):c.3556-13T>A  
NM\_000426.3(LAMA2):c.5235-18G>A  
NM\_000426.3(LAMA2):c.8989-12C>G  
NM\_000045.3(ARG1):c.306-611T>C  
NM\_000288.3(PEX7):c.-45C>T  
NM\_000941.2(POR):c.-5+4A>G  
NM\_000441.1(SLC26A4):c.-103T>C  
NM\_000441.1(SLC26A4):c.-60A>G  
NM\_000441.1(SLC26A4):c.-4+1G>C

NM\_000441.1(SLC26A4):c.-4+5G>A  
NM\_000441.1(SLC26A4):c.918+45\_918+47delCAA  
NM\_000441.1(SLC26A4):c.1150-35\_1150-28delTTTGTAGG  
NM\_000441.1(SLC26A4):c.1264-12T>A  
NM\_000441.1(SLC26A4):c.1438-7dupT  
NM\_000441.1(SLC26A4):c.1708-27\_1708-11delTAAGTAACTTGACATTT  
NM\_000441.1(SLC26A4):c.2090-52\_2090-49delCAAA  
NM\_000492.3(CFTR):c.-495C>T  
chr7:g.117119797-117119797  
NM\_000492.3(CFTR):c.-249G>C  
NM\_000492.3(CFTR):c.-165G>A  
NM\_000492.3(CFTR):c.-85C>G  
NM\_000492.3(CFTR):c.-34C>T  
NM\_000492.3(CFTR):c.53+124T>C  
NM\_000492.3(CFTR):c.870-1113\_870-1110delGAAT  
NM\_000492.3(CFTR):c.1117-26\_1117-25delAT  
NM\_000492.3(CFTR):c.1393-18G>A  
NM\_000492.3(CFTR):c.1585-9412A>G  
NM\_000492.3(CFTR):c.1585-19T>C  
NM\_000492.3(CFTR):c.1679+34G>T  
NM\_000492.3(CFTR):c.1680-886A>G  
NM\_000492.3(CFTR):c.1680-883A>G  
NM\_000492.3(CFTR):c.1680-877G>T  
NM\_000492.3(CFTR):c.2908+19G>C  
NM\_000492.3(CFTR):c.2909-15T>G  
NM\_000492.3(CFTR):c.2988+33G>T  
NM\_000492.3(CFTR):c.3140-26A>G  
NM\_000492.3(CFTR):c.3140-16T>A  
NM\_000492.3(CFTR):c.3140-11A>G  
NM\_000492.3(CFTR):c.3469-1304C>G  
NM\_000492.3(CFTR):c.3717+40A>G  
NM\_000492.3(CFTR):c.3718-2477C>T  
NM\_000492.3(CFTR):c.3873+33A>G  
NM\_000492.3(CFTR):c.3874-4522A>G  
NM\_000492.3(CFTR):c.\*1233T>A  
NM\_000083.2(CLCN1):c.-59C>A  
NM\_000083.2(CLCN1):c.1167-15\_1167-14delICT  
NM\_001017420.2(ESCO2):c.1354-18G>A  
NM\_000349.2(STAR):c.466-11T>A  
NM\_152419.2(HGSNAT):c.821-28\_821-10delTTGCTTATGCTTTGTACTT  
NM\_152416.3(NDUF6):c.298-768T>C  
NM\_152416.3(NDUF6):c.420+784C>T  
NM\_000497.3(CYP11B1):c.595+16G>T  
NM\_130849.3(SLC39A4):c.192+19G>A  
NM\_000155.3(GALT):c.-96T>G  
NM\_000155.3(GALT):c.83-11T>G  
NM\_000155.3(GALT):c.508-29delT  
NM\_000155.3(GALT):c.687+66T>A  
NM\_000155.3(GALT):c.820+13A>G  
NM\_000155.3(GALT):c.1059+56C>T  
chr9:g.35658026-35658026  
chr9:g.35658026-35658026  
chr9:g.35658026-35658026  
chr9:g.35658026-35658026  
chr9:g.35658027-35658027

chr9:g.35658027-35658027  
chr9:g.35658027-35658027  
chr9:g.35658027-35658027  
chr9:g.35658027-35658027  
chr9:g.35658028-35658028  
chr9:g.35658028-35658028  
chr9:g.35658029-35658029  
chr9:g.35658029-35658029  
chr9:g.35658032-35658032  
NM\_016042.3(EXOSC3):c.475-12A>G  
NM\_000136.2(FANCC):c.-78-2A>G  
NM\_000136.2(FANCC):c.-79+1G>A  
NM\_000380.3(XPA):c.390-12A>G  
NM\_000035.3(ALDOB):c.\*516T>A  
NM\_000035.3(ALDOB):c.-11+1G>C  
chr9:g.104198194-104198194  
NM\_006731.2(FKTN):c.648-1243G>T  
NM\_000050.4(ASS1):c.-5-10C>G  
NM\_000050.4(ASS1):c.175-1119G>A  
NM\_000050.4(ASS1):c.773+49C>T  
NM\_007171.3(POMT1):c.-30-2A>G  
NM\_003172.3(SURF1):c.324-11T>G  
NM\_001173454.1(PDHA1):c.533-17\_533-14delTGTT  
NM\_001173454.1(PDHA1):c.625-30G>A  
NM\_001173454.1(PDHA1):c.873+26G>A  
NM\_001173454.1(PDHA1):c.\*79\_\*90dupAGTCAATGAAAT  
NM\_001173454.1(PDHA1):c.\*79\_\*90dupAGTCAATGAAAT  
NM\_004006.2(DMD):c.10554-18C>G  
NM\_004006.2(DMD):c.9974+175T>A  
NM\_004006.2(DMD):c.9564-30A>T  
NM\_004006.2(DMD):c.9564-427T>G  
NM\_004006.2(DMD):c.9563+1215A>G  
NM\_004006.2(DMD):c.9362-1215A>G  
NM\_004006.2(DMD):c.9361+117A>G  
NM\_004006.2(DMD):c.9225-160A>G  
NM\_004006.2(DMD):c.9225-285A>G  
NM\_004006.2(DMD):c.9225-287C>A  
NM\_004006.2(DMD):c.9225-647A>G  
NM\_004006.2(DMD):c.9225-648A>G  
NM\_004006.2(DMD):c.9224+9192C>A  
NM\_004006.2(DMD):c.9085-15519G>T  
NM\_004006.2(DMD):c.8217+32103G>T  
NM\_004006.2(DMD):c.8217+18052A>G  
NM\_004006.2(DMD):c.7661-11T>C  
NM\_004006.2(DMD):c.6913-4037T>G  
NM\_004006.2(DMD):c.6614+3310G>T  
NM\_004006.2(DMD):c.6290+30954C>T  
NM\_004006.2(DMD):c.6118-15A>G  
NM\_004006.2(DMD):c.5740-15G>T  
NM\_004006.2(DMD):c.5326-215T>G  
NM\_004006.2(DMD):c.5325+1743\_5325+1760delTATTAATAAATGGGTAGA  
NM\_004006.2(DMD):c.4675-11A>G  
NM\_004006.2(DMD):c.3787-843C>A  
NM\_004006.2(DMD):c.3603+2053G>C  
NM\_004006.2(DMD):c.3432+2240A>G

NM\_004006.2(DMD):c.3432+2036A>G  
NM\_004006.2(DMD):c.961-5831C>T  
NM\_004006.2(DMD):c.961-5925A>C  
NM\_004006.2(DMD):c.832-15A>G  
NM\_004006.2(DMD):c.650-39498A>G  
NM\_004006.2(DMD):c.531-16T>A  
NM\_004006.2(DMD):c.531-16T>G  
NM\_004006.2(DMD):c.531-16T>A/G  
NM\_004006.2(DMD):c.265-463A>G  
NM\_004006.2(DMD):c.93+5590T>A  
NM\_004006.2(DMD):c.31+36947G>A  
NM\_004006.2(DMD):c.-54T>A  
NM\_000397.3(CYBB):c.-69A>C  
chrX:g.37639262-37639262  
NM\_000397.3(CYBB):c.-67T>C  
NM\_000397.3(CYBB):c.-65C>T  
NM\_000397.3(CYBB):c.-64C>T  
NM\_000397.3(CYBB):c.46-14\_46-11delTTCTinsGAA  
NM\_000397.3(CYBB):c.46-11T>G  
NM\_000397.3(CYBB):c.142-28\_142-12delACTCTGCTCCCTTTCCC  
NM\_000397.3(CYBB):c.142-12delCinsACCTCTTCTAG  
NM\_000397.3(CYBB):c.483+978G>T  
NM\_000397.3(CYBB):c.674+1080A>G  
NM\_000397.3(CYBB):c.674+1337T>G  
NM\_000397.3(CYBB):c.675-1157A>G  
NM\_000397.3(CYBB):c.1152-11T>G  
chrX:g.38128234-38128234  
NM\_001034853.1(RPGR):c.1059+363G>A  
NM\_000531.5(OTC):c.-9384G>T  
chrX:g.38211584-38211584  
NM\_000531.5(OTC):c.-157T>G  
NM\_000531.5(OTC):c.-142G>A  
NM\_000531.5(OTC):c.-139A>G  
NM\_000531.5(OTC):c.-116C>T  
NM\_000531.5(OTC):c.-115C>T  
NM\_000531.5(OTC):c.-106C>A  
NM\_000531.5(OTC):c.540+265G>A  
NM\_000531.5(OTC):c.867+1126A>G  
NM\_000531.5(OTC):c.1005+1091C>G  
NM\_000044.3(AR):c.-547C>T  
NM\_000044.3(AR):c.1616+22072A>C  
NM\_000044.3(AR):c.1769-11T>A  
NM\_000044.3(AR):c.2450-118A>G  
NM\_000044.3(AR):c.2450-42G>A  
NM\_001399.4(EDA):c.707-13T>C/G  
NM\_001399.4(EDA):c.707-13T>C  
NM\_001399.4(EDA):c.707-13T>G  
NM\_000206.2(IL2RG):c.\*307\_\*308delIAA  
NM\_000206.2(IL2RG):c.\*308A>G  
NM\_000206.2(IL2RG):c.270-15A>G  
NM\_000206.2(IL2RG):c.-105C>T  
NM\_001097642.2(GJB1):c.-16-576\_-16-575insT  
NM\_001097642.2(GJB1):c.-16-524C>G  
NM\_001097642.2(GJB1):c.-16-513T>C/G  
NM\_001097642.2(GJB1):c.-16-513T>C

NM\_001097642.2(*GJB1*):c.-16-513T>G  
 NM\_001097642.2(*GJB1*):c.-16-511G>C  
 NM\_000166.5(*GJB1*):c.-103C>T  
 NM\_000166.5(*GJB1*):c.-17G>A  
 NM\_000166.5(*GJB1*):c.-17+1G>T  
 NM\_000166.5(*GJB1*):c.-17+2T>C  
 NM\_001097642.2(*GJB1*):c.-16-3C>G  
 NM\_001097642.2(*GJB1*):c.-16-2A>G  
 NM\_001097642.2(*GJB1*):c.-16-1G>A  
 NM\_001097642.2(*GJB1*):c.\*15C>T  
 NM\_000052.5(*ATP7A*):c.2916+2480T>G  
 NM\_000052.5(*ATP7A*):c.3294+763C>G  
 NM\_000390.2(*CHM*):c.315-1536A>G  
 NM\_000390.2(*CHM*):c.315-4587T>A  
 chrX:g.85302626-85302626  
 chrX:g.85302634-85302634  
 chrX:g.85302634-85302634  
 chrX:g.85302644-85302644  
 NM\_000169.2(*GLA*):c.640-11T>A  
 NM\_000169.2(*GLA*):c.640-801G>A  
 NM\_000169.2(*GLA*):c.640-859C>T  
 NM\_000169.2(*GLA*):c.547+395G>C  
 NM\_000533.3(*PLP1*):c.4+78\_4+85delGGGGGTTC  
 NM\_000533.3(*PLP1*):c.453+28\_453+46delTAACAAGGGGTGGGGGAAA  
 NM\_000533.3(*PLP1*):c.454-322G>A  
 NM\_000533.3(*PLP1*):c.454-314T>A/G  
 NM\_000533.3(*PLP1*):c.454-314T>A  
 NM\_000533.3(*PLP1*):c.454-314T>G  
 NM\_033380.2(*COL4A5*):c.385-719G>A  
 NM\_033380.2(*COL4A5*):c.466-12G>A  
 NM\_033380.2(*COL4A5*):c.609+875G>T  
 NM\_033380.2(*COL4A5*):c.646-12\_646-11delTT  
 NM\_033380.2(*COL4A5*):c.1423+57dupC  
 NM\_033380.2(*COL4A5*):c.1424-20T>A  
 NM\_033380.2(*COL4A5*):c.1948+894C>G  
 NM\_033380.2(*COL4A5*):c.2042-18A>G  
 NM\_033380.2(*COL4A5*):c.2245-40A>G  
 NM\_033380.2(*COL4A5*):c.2245-14T>A  
 NM\_033380.2(*COL4A5*):c.2395+2750A>G  
 NM\_033380.2(*COL4A5*):c.3374-11C>A  
 NM\_033380.2(*COL4A5*):c.4529-2300T>G  
 NM\_033380.2(*COL4A5*):c.4529-345A>G  
 NM\_033380.2(*COL4A5*):c.4821+121T>C  
 NM\_033380.2(*COL4A5*):c.4822-152dupT  
 NM\_033380.2(*COL4A5*):c.4822-151\_4822-150insT  
 NM\_004208.3(*AIFM1*):c.697-44T>G  
 NM\_004208.3(*AIFM1*):c.-123G>C  
 NM\_000194.2(*HPRT1*):c.27+47C>T  
 NM\_000194.2(*HPRT1*):c.402+1229A>G  
 NM\_000194.2(*HPRT1*):c.485+1202T>A  
 NM\_000194.2(*HPRT1*):c.533-13T>G  
 NM\_000074.2(*CD40LG*):c.289-32\_289-25delAAAATGAC  
 NM\_000074.2(*CD40LG*):c.289-15T>A  
 NM\_000074.2(*CD40LG*):c.347-915A>T  
 NM\_000133.3(*F9*):c.-55G>A/C/T



chrX:g.138612869-138612869  
chrX:g.138612869-138612869  
chrX:g.138612869-138612869  
NM\_000133.3(F9):c.-53A>G  
chrX:g.138612871-138612871  
NM\_000133.3(F9):c.-52C>G/T  
chrX:g.138612872-138612872  
chrX:g.138612872-138612872  
NM\_000133.3(F9):c.-50T>C/G  
chrX:g.138612874-138612874  
chrX:g.138612874-138612874  
NM\_000133.3(F9):c.-49T>A/C  
chrX:g.138612875-138612875  
chrX:g.138612875-138612875  
NM\_000133.3(F9):c.-48G>C  
NM\_000133.3(F9):c.-38A>G  
NM\_000133.3(F9):c.-35G>A/C  
chrX:g.138612889-138612889  
chrX:g.138612889-138612889  
NM\_000133.3(F9):c.-34A>G/T  
chrX:g.138612890-138612890  
chrX:g.138612890-138612890  
NM\_000133.3(F9):c.-22delT  
NM\_000133.3(F9):c.-24T>A  
NM\_000133.3(F9):c.-23T>C  
NM\_000133.3(F9):c.-22T>C  
NM\_000133.3(F9):c.-21C>G  
NM\_000133.3(F9):c.-19C>G  
NM\_000133.3(F9):c.-17delA  
NM\_000133.3(F9):c.-18A>G/T  
NM\_000133.3(F9):c.-18A>T  
NM\_000133.3(F9):c.-18A>G  
NM\_000133.3(F9):c.-17A>C/G  
NM\_000133.3(F9):c.-17A>C  
NM\_000133.3(F9):c.-17A>G  
NM\_000133.3(F9):c.253-25A>G/T  
NM\_000133.3(F9):c.253-25A>T  
NM\_000133.3(F9):c.253-25A>G  
NM\_000133.3(F9):c.253-19\_253-16delCTTC  
NM\_000133.3(F9):c.253-16\_253-12delCTTTT  
NM\_000133.3(F9):c.278-13A>G  
NM\_000133.3(F9):c.278-12C>G/T  
NM\_000133.3(F9):c.278-12C>G  
NM\_000133.3(F9):c.278-12C>T  
NM\_000133.3(F9):c.392-22\_392-21delCT  
NM\_000133.3(F9):c.520+13A>G  
NM\_000133.3(F9):c.723+18T>A  
NM\_000133.3(F9):c.\*1157A>G  
NM\_000133.3(F9):c.\*1368A>G  
NM\_000202.5(IDS):c.1181-15C>A  
NM\_006123.4(IDS):c.\*57A>G  
NM\_000202.5(IDS):c.709-657G>A  
NM\_000252.2(MTM1):c.137-19\_137-16delACTT  
NM\_000252.2(MTM1):c.137-11T>A  
NM\_000252.2(MTM1):c.232-26\_232-23delGACT

NM\_000252.2(MTM1):c.529-909A>G  
 NM\_000252.2(MTM1):c.868-13T>A  
 NM\_000425.4(L1CAM):c.3531-12G>A  
 NM\_000425.4(L1CAM):c.2432-19A>C  
 NM\_000425.4(L1CAM):c.1704-75G>T  
 NM\_000425.4(L1CAM):c.1547-14delC  
 NM\_000425.4(L1CAM):c.523+12C>T  
 NM\_000117.2(EMD):c.266-27\_266-10delTCTGCTACCGCTGCCCCC  
 NM\_001363.3(DKC1):c.-142C>G  
 NM\_001363.3(DKC1):c.-141C>G  
 NM\_001363.3(DKC1):c.85-15T>C

## GLOSSARY OF USED ABBREVIATIONS:

**AD** = autosomal dominant

**AF** = allele fraction (proportion of reads with mutated DNA / all reads)

**AR** = autosomal recessive

**CNV** = Copy Number Variation e.g. one exon or multiexon deletion or duplication

**gnomAD** = genome Aggregation Database (reference population database; >138,600 individuals)

**gnomAD AC/AN** = allele count/allele number in the genome Aggregation Database (gnomAD)

**HEM** = hemizygous

**HET** = heterozygous

**HOM** = homozygous

**ID** = rsID in dbSNP

**MT** = Mitochondria

**MutationTaster** = *in silico* prediction tools used to evaluate the significance of identified amino acid changes.

**Nomenclature** = HGVS nomenclature for a variant in the nucleotide and the predicted effect of a variant in the protein level

**OMIM** = Online Mendelian Inheritance in Man®

**PolyPhen** = *in silico* prediction tool used to evaluate the significance of amino acid changes.

**POS** = genomic position of the variant in the format of chromosome:position

**SIFT** = *in silico* prediction tool used to evaluate the significance of amino acid changes.